{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=latanoprost",
    "query": {
      "intervention": "latanoprost"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 122,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=latanoprost&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T20:28:28.315Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01253902",
      "title": "Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma, Open-Angle",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "bimatoprost ophthalmic solution 0.01%",
          "type": "DRUG"
        },
        {
          "name": "travoprost ophthalmic solution 0.004%",
          "type": "DRUG"
        },
        {
          "name": "latanoprost ophthalmic solution 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2010-12",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2012-11-07",
      "last_synced_at": "2026-09-12T20:28:28.315Z",
      "location_count": 1,
      "location_summary": "Rogers, Arkansas",
      "locations": [
        {
          "city": "Rogers",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01253902"
    },
    {
      "nct_id": "NCT01180062",
      "title": "Safety Study of Latanoprost Slow Release Insert",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma (POAG)",
        "Ocular Hypertension (OHT)"
      ],
      "interventions": [
        {
          "name": "Latanoprost",
          "type": "DRUG"
        },
        {
          "name": "Arm 2",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost SR insert",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daniel Moore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2011-01",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-12-08",
      "last_synced_at": "2026-09-12T20:28:28.315Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01180062"
    },
    {
      "nct_id": "NCT00277498",
      "title": "A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Xalacom",
          "type": "DRUG"
        },
        {
          "name": "Xalatan",
          "type": "DRUG"
        },
        {
          "name": "Timolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 528,
      "start_date": "2005-12",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-09-12T20:28:28.315Z",
      "location_count": 64,
      "location_summary": "Birmingham, Alabama • Flagstaff, Arizona • Artesia, California + 52 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00277498"
    },
    {
      "nct_id": "NCT00947661",
      "title": "Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "SPARC0912",
          "type": "DRUG"
        },
        {
          "name": "Reference0912",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharma Advanced Research Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 578,
      "start_date": "2010-07",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2021-03-09",
      "last_synced_at": "2026-09-12T20:28:28.315Z",
      "location_count": 1,
      "location_summary": "High Point, North Carolina",
      "locations": [
        {
          "city": "High Point",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00947661"
    },
    {
      "nct_id": "NCT01060579",
      "title": "Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "AR-12286 0.5% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "AR-12286 0.25% Ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 217,
      "start_date": "2010-02",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2014-05-08",
      "last_synced_at": "2026-09-12T20:28:28.315Z",
      "location_count": 18,
      "location_summary": "Inglewood, California • Petaluma, California • Poway, California + 15 more",
      "locations": [
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        },
        {
          "city": "Stuart",
          "state": "Florida"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01060579"
    },
    {
      "nct_id": "NCT07465913",
      "title": "Rocklatan vs Latanoprost Post-DSLT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Rocklatan 0.02%-0.005% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eye Centers of Southeast Texas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2026-05-14",
      "completion_date": "2027-05-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-09-12T20:28:28.315Z",
      "location_count": 1,
      "location_summary": "Beaumont, Texas",
      "locations": [
        {
          "city": "Beaumont",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07465913"
    },
    {
      "nct_id": "NCT02167035",
      "title": "Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Combigan Two Times Daily (BID)",
          "type": "DRUG"
        },
        {
          "name": "Simbrinza Three Times Daily (TID)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cornerstone Health Care, PA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2014-08",
      "completion_date": "2018-03",
      "has_results": true,
      "last_update_posted_date": "2018-10-24",
      "last_synced_at": "2026-09-12T20:28:28.315Z",
      "location_count": 1,
      "location_summary": "High Point, North Carolina",
      "locations": [
        {
          "city": "High Point",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02167035"
    },
    {
      "nct_id": "NCT01917383",
      "title": "A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Open-Angle Glaucoma (POAG)",
        "Ocular Hypertension (OHT)"
      ],
      "interventions": [
        {
          "name": "Trabodenoson",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost",
          "type": "DRUG"
        },
        {
          "name": "Timolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inotek Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2013-08",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2017-12-02",
      "last_synced_at": "2026-09-12T20:28:28.315Z",
      "location_count": 1,
      "location_summary": "Bristol, Tennessee",
      "locations": [
        {
          "city": "Bristol",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01917383"
    },
    {
      "nct_id": "NCT02138461",
      "title": "Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "MDbackline, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 211,
      "start_date": "2013-10",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2014-09-25",
      "last_synced_at": "2026-09-12T20:28:28.315Z",
      "location_count": 1,
      "location_summary": "Laguna Hills, California",
      "locations": [
        {
          "city": "Laguna Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02138461"
    },
    {
      "nct_id": "NCT00811564",
      "title": "An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "latanoprost 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 148,
      "start_date": "2008-12",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2011-09-21",
      "last_synced_at": "2026-09-12T20:28:28.315Z",
      "location_count": 1,
      "location_summary": "Slingerlands, New York",
      "locations": [
        {
          "city": "Slingerlands",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00811564"
    }
  ]
}